POST Online Media Lite Edition



 

Capstone Therapeutics appoints Robert J. Spiegel to board of directors

Staff writer |
Tempe, Ariz., USA - May 25, 2010, Tempe, Ariz., USA - Capstone Therapeutics Corp., a biotechnology company, announced the appointment of Robert J. Spiegel to its board of directors.



Dr. Spiegel has more than 25 years of executive-level pharmaceutical development and product commercialization experience with Schering-Plough. Until his retirement in November 2009, Dr. Spiegel held the position of Chief Medical Officer at Schering-Plough and was a member of their Pharmaceutical Leadership Board and Corporate Licensing Review Board; he was also Chairman of Schering-Plough's Safety Review Board and Preparedness Response Committee (Crisis Control).

While with Schering-Plough, Dr. Spiegel was involved in the filing of over thirty NDA submissions and interacted with US FDA and EU regulatory authorities on a regular basis, serving on the executive committees overseeing all research projects and drug licensing activities. He also served as the lead Schering-Plough representative in numerous joint venture development projects with biotechnology and other large pharmaceutical partnerships.

Dr. Spiegel originally joined Schering-Plough as Director, Clinical Research, progressing through clinical operations as Vice President, Clinical Research, Senior Vice President, Worldwide Clinical Research, becoming Chief Medical Officer in 1998.

LATEST 5 MOVES FROM  


What to read next

Delek Logistics expands its board
PTC Therapeutics names Tuyen Ong as chief medical officer
Capstone Mining appoints director